All references to the study being a “Phase III” clinical trial were finally removed, and some of the flaws in the study’s methodology were cited, but underplayed.However, they still managed too sneak in some “marketing jargon” into their conclusions, such as “remarkably, the effects seen from the product came from a single application.” We had to laugh when we read that line in a medical journal, since the word “remarkably” was clearly marketing hype.
In a research “summary” posted on Dynamiclear’s site, they claim that the option of testing Dynamiclear against a Placebo (i.e.Or they recommend products that result in affiliate income for them – and do not disclose that relationship. At the time that this warning letter was written, Global Herbal Supplies was the main worldwide marketer and distributor of Choraphor.Unfortunately, since Global Herbal Supplies is based in Australia, not the US, it is hard for the FDA to enforce its warnings against non-US companies who make misleading or deceptive marketing claims.Unfortunately, it can be very difficult to tell the difference between scammers and real people, and to discern online charlatans from real doctors or experts.Some sites post both good information alongside bad information – to make them sound credible. Please note that there are many other bogus STD treatments that the FDA might have wanted to include on this list, but were unable to include or enforce because of various factors, such as: the companies were not physically located within the United States, or their locations were unclear, or the websites that made the false claims about the product could not be easily traced back to the company that made it. Prior to introducing Dynamiclear, Global Herbal Supplies, an Australia-based company that makes and markets herbal remedies, manufactured and marketed a single-application topical herpes treatment called “Choraphor.” In July 2006, the FDA issued a warning letter to the marketers of Choraphor (Global Herbal Supplies) due to their practice of making false and misleading marketing claims about Choraphor.So basically, a clinical study that has such major flaws cannot be trusted to prove much of anything.Interestingly, even though this clinical trial was done in 2006, it was not until February 2012 that an abstract of the results were published in the Journal of Drugs in Dermatology.The “clinical trials” commissioned by Global Herbal Supplies in 2006 and performed in India were extremely poorly conceived and designed, with only 149 subjects, 120 of whom completed the study; only 30% of subjects were female, and only 34% of the subjects had genital herpes.The study lasted only 14 days, did NOT include a control group, was NOT double-blind, did NOT record time of onset NOR the recurrency rate, and did NOT distinguish between primary or secondary infections.In August 2012, after receiving criticism and complaints from the Herpes Support Community, Global Herbal Supplies made corrections to their web-pages, removing the claim that their clinical trials were “Phase III”.However, previously downloaded copies of Dynamiclear’s own summary of their research show that they had been mislabeling this as a “Phase III” clinical trial from 2006 until August 2012.